Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808418 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 5
- Study locations
NCT00808418: Completed Phase 1 study of Prostate Cancer, sponsored by Synta Pharmaceuticals.
NCT00808418 is a Phase 1 study of Prostate Cancer that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 34 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00808418, a Phase 1 study of Prostate Cancer, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 5
- Study locations
Study Summary
This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomol and docetaxel.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Elesclomol Sodium
Study Locations (5)
California
- Pacific Coast Hematology/Oncology Medical Group - Fountain Valley
Maryland
- Mayo Clinic - Rochester
North Dakota
- Mid Dakota Clinic - Bismarck
Texas
- University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development - San Antonio
Wisconsin
- University of Wisconsin Paul P. Carbone Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808418
The ClinicalTrials.gov registry entry for NCT00808418 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT00808418 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Maryland, North Dakota.
Frequently Asked Questions
What is clinical trial NCT00808418 about?
NCT00808418 is a clinical study titled "A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer". This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. This study will also characterize the pharmacokinetics of elesclomo...
What is the current status of trial NCT00808418?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2008-11. Estimated completion is 2010-05.
What conditions does trial NCT00808418 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00808418?
The interventions under investigation include: Docetaxel (DRUG), Elesclomol Sodium (DRUG).
Who is sponsoring clinical trial NCT00808418?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808418 being conducted?
This trial has 5 study locations across California, Maryland, North Dakota, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.